drugset

drugset / Trial / NCT02369016

Phase III Copanlisib in Rituximab-refractory iNHL

NCT02369016 ↗

Phase 3 Completed 25 enrolled Bayer

NaSingle-groupOpen-labelTreatment

Summary

To assess the safety of copanlisib.

Timeline

Start: 2015-09-22
Primary completion: 2022-10-26
Completion: 2022-10-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Copanlisib	Small molecule	60 mg	Intravenous

Indications